Jpmorgan Chase & CO Atossa Therapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ATOS
# of Institutions
89Shares Held
26.5MCall Options Held
466KPut Options Held
91.8K-
Black Rock Inc. New York, NY9.2MShares$9.47 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.6MShares$6.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.81MShares$2.9 Million0.0% of portfolio
-
State Street Corp Boston, MA1.73MShares$1.78 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.31MShares$1.35 Million0.0% of portfolio
About ATOSSA THERAPEUTICS, INC.
- Ticker ATOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 126,624,000
- Market Cap $130M
- Description
- Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...